Conditions

Subcategories:Axial Spondyloarthritis Gout and Crystalline Arthritis Guidelines Myositis Osteoarthritis and Bone Disorders Other Rheumatic Conditions Pain Syndromes Pediatric Conditions Psoriatic Arthritis Rheumatoid Arthritis Sjögren’s Disease Soft Tissue Pain Systemic Lupus Erythematosus Systemic Sclerosis Vasculitis

Single-Cell Technologies: A Path for New Insights

Lara C. Pullen, PhD | December 7, 2020

This ACR Convergence session discussed how recent advances in single-cell technologies are being used in rheumatic disease research.

10 Clinical Insights from Rheumatology Top Secrets & Pearls

Vanessa Caceres | December 7, 2020

In this ACR Convergence session, Jason R. Kolfenbach, MD, & John H. Stone, MD, MPH, shared clinical insights about rheumatic diseases.

A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review

Jason Liebowitz, MD, FACR | December 7, 2020

During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.

Antiphospholipid Syndrome: Management & Future Directions

Lara C. Pullen, PhD | December 4, 2020

Three experts discuss recent developments in the diagnosis & treatment of APS & the future direction of research.

COVID-19 Risks & Treatment for Patients with Rheumatic Disease

Thomas R. Collins | December 4, 2020

The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.

Resetting Immune Tolerance to Prevent RA

Mary Beth Nierengarten | November 24, 2020

Three experts discuss the current evidence on potential pathogenic mechanisms underlying preclinical RA autoimmunity and subsequent active disease.

Pulmonary Adverse Events with Low-Dose Methotrexate

Arthritis & Rheumatology | November 24, 2020

In this large placebo-controlled trial, Sparks et al. examined the predictors and severity of pulmonary adverse events (AEs) in patients taking low-dose MTX. The researchers found that low-dose MTX increased the risk of pulmonary AEs, including possible pneumonitis.

2020 Pediatric Rheumatology Research in Review

Carina Stanton | November 24, 2020

ACR CONVERGENCE 2020—This has been a busy year for research publications covering a number of pediatric rheumatic diseases, including the emerging multi-system inflammatory syndrome (MIS-C) associated with SARS CoV-2. Despite the many challenges brought about by the COVID-19 pandemic, a healthy collection of publications covering a wide range of pediatric rheumatology research topics were published…

Osteoporosis Experts Discuss Bisphosphonate Holidays

Susan Bernstein | November 24, 2020

ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

Vanessa Caceres | November 24, 2020

ACR CONVERGENCE 2020—Patients with rheumatoid arthritis (RA) and concurrent liver disease or interstitial lung disease (ILD), or with treatment-refractory RA, pose treatment challenges, said panelists in the ACR Convergence 2020 session, How I Treat Difficult RA. Each panelist discussed a difficult case and raised big-picture questions on how to best treat patients facing each challenge….